CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
Rhea-AI Summary
CollPlant (Nasdaq: CLGN) announced the Korean Patent Office allowed a patent for its photocurable dermal filler covering a polymerizable rhCollagen solution for in situ light-activated tissue augmentation.
The allowance extends protection through 2039, follows a recent Japanese grant, and adds to granted patents in the US, Europe, China, Brazil, Australia, and Israel. According to the company, the global injectable soft-tissue filler market exceeds $6 billion. CollPlant noted a 2021 development and global commercialization agreement with Allergan (AbbVie).
Positive
- Korean patent allowed covering photocurable rhCollagen filler through 2039
- Broader patent portfolio with grants in US, Europe, China, Brazil, Australia, and Israel
- Commercial partner relationship: 2021 development and global commercialization agreement with Allergan (AbbVie)
- Addresses large market in injectables, market estimated to exceed $6 billion
Negative
- Product still under development; commercialization contingent on completing development
- No clinical or regulatory timelines disclosed for market approval or launch
Key Figures
Market Reality Check
Peers on Argus
CLGN was down 4.68% while only one peer in the momentum set (DYAI) also moved down (-4.09%), with no same-day news across peers, pointing to a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Product launch | Positive | -3.2% | Launch of BioFlex rhCollagen ready-to-print 3D bioprinting kit. |
| Feb 17 | Strategic positioning | Positive | -11.9% | Positioning photocurable dermal filler for GLP-1-related facial volume loss. |
| Feb 05 | Capital raise | Negative | -53.4% | Registered direct equity offering with Series A and B warrants. |
| Nov 26 | Earnings update | Positive | -0.5% | Q3 2025 results with higher revenue, narrowed loss, and cost reductions. |
| Nov 18 | Earnings date notice | Neutral | +0.9% | Announcement of reporting date for Q3 2025 financial results. |
Recent positive product and strategy announcements often coincided with negative next-day moves, while dilutive capital raises aligned with sharp declines.
Over the last few months, CollPlant has combined strategic product launches and platform positioning with balance sheet actions. On Feb 5, 2026, a $2.0M registered direct offering with warrants led to a -53.42% move, underscoring sensitivity to dilution. Product-focused updates on Feb 17 (GLP-1-related dermal filler) and Feb 23 (BioFlex launch) both saw selling pressure despite strategic relevance. Earlier, Q3 2025 results on Nov 26 showed higher revenue and cost reductions but produced little price benefit. Today’s Korean patent allowance fits into this pattern of IP and platform-building news against a weak share-price backdrop.
Market Pulse Summary
This announcement secures Korean patent protection through 2039 for CollPlant’s photocurable rhCollagen-based dermal filler, reinforcing its IP footprint in a key aesthetic market. The platform targets a global injectable filler segment estimated above $6 billion and follows recent strategic moves around GLP-1-driven aesthetics and new bioink products. Against a backdrop of recent capital raises and modest revenue, investors may watch how this IP position translates into collaborations, regulatory milestones, and eventual commercialization steps for the filler platform.
Key Terms
photocurable dermal filler medical
polymerizable solution medical
3D bioprinting medical
AI-generated analysis. Not financial advice.
- Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product Candidate
REHOVOT,
The allowed patent application covers a polymerizable solution and its use in tissue augmentation. The composition is injected into a sub-epidermal tissue space and subsequently polymerized in situ using external light activation. This invention underpins CollPlant's proprietary photocuring platform for dermal fillers.
"This patent allowance represents another important milestone in executing our strategy to expand the clinical and commercial applications of our rhCollagen platform into high-value aesthetic markets," said Yehiel Tal, Chief Executive Officer of CollPlant. "
Mr. Tal added, "Beyond skin lifting, our photocurable rhCollagen-based filler platform was designed to support structural tissue restoration. Upon light activation, the material forms a supportive scaffold intended to enhance long-term contour stability. The technology is designed not only to restore facial contours but also to provide a regenerative matrix that may promote tissue integration and durable structural improvement. With patent protection extending through 2039, we believe this innovation positions us to compete effectively, upon completion of development, in a global injectable soft-tissue filler market currently estimated to exceed
The polymerizable formulation comprises chemically modified rhCollagen together with additional constituents, including a hyaluronic acid-based filler component. The solution is engineered to exhibit viscosity suitable for extrusion through a surgical needle of at least 27-gauge at the temperature of use, while enabling post-injection contour modulation before, during or after light-induced curing.
The Korean patent allowance follows the recent grant of a Japanese patent covering, among other things, a photocurable dermal filler kit and related polymerizable compositions comprising chemically modified rhCollagen for use in tissue augmentation. These compositions are introduced into a sub-epidermal tissue space and induced to polymerize upon light activation. CollPlant's photocuring technology is further protected by granted patents in
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit http://www.collplant.com.
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives, plans and strategies, including the potential benefits and advantages of a Korean patent, the estimated global injectable soft-tissue filler market size,, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. Further, The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or it strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based bioink and medical aesthetics products or product candidates including, but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in
Contacts:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@CollPlant.com
Photo - https://mma.prnewswire.com/media/2921182/CollPlant.jpg
Logo - https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-korean-patent-allowance-secured-for-its-photocurable-dermal-filler-302698310.html
SOURCE CollPlant
FAQ
What did CollPlant (CLGN) announce on February 26, 2026 about its dermal filler patent in Korea?
How long does the newly allowed Korean patent for CollPlant's (CLGN) photocurable filler last?
Does the Korean patent for CollPlant (CLGN) cover the composition and use of the photocurable dermal filler?
What commercial significance does the Korean patent have for CollPlant (CLGN)?
Has CollPlant (CLGN) secured similar patents in other countries for its photocurable filler?
Is CollPlant's photocurable dermal filler commercially available now for investors (CLGN)?
